Munich Re and Microsoft helped CO2-to-chemicals technology provider Twelve raise $57m while Eli Lilly and Kaiser Permanente-backed CRO dMed-Clinipac secured $50m.
Funding
Twelve, a US-based developer of technology which converts carbon dioxide to chemicals, secured $57m yesterday in a series A round featuring reinsurance firm Munich Re’s investment arm, Munich Re Ventures, as well as software producer Microsoft’s Climate Innovation Fund. The round was co-led by Capricorn Technology Impact Fund and Carbon Direct Capital Management and also backed by Breakout Ventures, Evok Innovations and DCVC, the last of which, the company, said led its seed round. It was previously known as…
